Pharming gets FDA approval for new facility to make HAE drug Ruconest

Pharming Group last year took back control of Ruconest, its treatment for protein deficiency hereditary angioedema. Now, it has gained approvals for a new manufacturing facility that will ensure it has sufficient supplies for the drug.